Compare OPK & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPK | EVO |
|---|---|---|
| Founded | 2006 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 921.2M | 934.1M |
| IPO Year | 2011 | N/A |
| Metric | OPK | EVO |
|---|---|---|
| Price | $1.29 | $3.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $1.60 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 2.3M | 85.0K |
| Earning Date | 04-28-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $606,879,000.00 | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $4.24 | $10.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.98 | $2.31 |
| 52 Week High | $1.60 | $4.48 |
| Indicator | OPK | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 71.83 | 53.04 |
| Support Level | $1.28 | $2.88 |
| Resistance Level | $1.42 | $3.36 |
| Average True Range (ATR) | 0.04 | 0.09 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 93.33 | 54.34 |
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.